Pharmafile Logo

What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?

December 23, 2025 |  

Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.

lucy                           Picture1megan

Lucy McKay                                                  Megan Pullein
CEO                                                                Strategic Operations Officer
Medics for Rare Disease                            Medics for Rare Disease

Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?

Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.

Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.

Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?

Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.

Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?

Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.

Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.

Christy: Where does the work for each group start, and where does it end?

Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?

The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.

The final phase will be to consolidate this evidence into concrete recommendations.

Christy: What do you find most exciting about RDI-Lancet Commission?

Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.

It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.

Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.

For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract

About Medscape Education

Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional

This content was provided by Medscape Education

Company Details

 Latest Content from  Medscape Education 

Leading the Way at ESC 2024

Anticipation is building at Medscape Education as the team prepares for the ESC 2024 Congress. We are excited to announce a significant presence during the congress including a booth (#H500)...

Always Be in a Growth Mindset: Chief Strategy Officer Christina Hoffman’s Return to Her Education Roots

Medicine is always changing, and the career of Medscape Education’s Chief Strategy Officer, Christina Hoffman, is no exception. The 17-year Medscape veteran recently said goodbye to her role as leader...

Medscape Education Showcases Unprecedented Achievements at EHA 2024

Medscape Education is proud to share its monumental success at the EHA 2024 Congress. Our continued commitment to patient-centric medical education was evident throughout the event, with notable achievements and...

Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations

“I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...

Medscape Education Demonstrates Strong Education Outcomes at the American Diabetes Association 2024 Conference

Medscape Education presented seven scientific posters at this year’s American Diabetes Association (ADA) conference in Orlando, Florida. These posters highlighted the outcomes of Medscape Education’s continuing medical education programs, which...

Stemming the Flow–Medscape Presents at HLTH Europe

Medscape Education will be attending HLTH Europe from June 17-20. Be sure to drop by our booth to participate in our survey and enjoy exciting giveaways. Additionally, Dr. John Whyte,...

Medscape Education to Emphasize the Role of Education in Digital Therapeutics at DTA Summit

As a leader in medical education and proud sponsor of the 2024 Digital Therapeutics Summit, Medscape is excited to announce that Medscape Education’s Chief Strategy Officer, Christina Hoffman, will be...

Medscape Oncology to Make a Significant Impact at ASCO 2024

ASCO is one of the biggest conferences of the year for Medscape Oncology, and the team is ready to make an impact in Chicago. They’ll be manning booth #26030, where...

Medscape Oncology Launches Inaugural Medscape Fellows Program at ASCO 2024

Medscape Oncology is excited to announce the launch of the first-ever Medscape Fellows Program at the 2024 ASCO meeting in Chicago, Illinois. This groundbreaking program aims to nurture young oncology...

Navigating Food Allergy Management: Trends, Treatments, and Decision-Making

Are you having trouble navigating the management of food allergies? Join our faculty experts for a live conversation on social media to learn about the evolving complexities in food allergy...